Breaking News, Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales were up 5% in the quarter to $11.4 billion.

By: Contract Pharma

Contract Pharma Staff

Financial Report: Johnson & Johnson 3Q Revenues: $21.1 billion (+2%) 3Q Earnings: $3.6 billion (+103%) YTD Revenues: $60.1 billion (-2%) YTD Earnings: $13.0 billion (+17%) Comments: Pharmaceutical sales were $11.4 billion in the quarter, up 5%, driven by DARZALEX (+44% to $1.1 billion) for the treatment of multiple myeloma, STELARA (+15% to $1.9 billion) for the treatment of a number of immune-mediated inflammatory diseases, IMBRUVICA (+12% to $1.0 billion) for use in treating certain B...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters